NVO - Aeterna Zentaris licensing partner Consilient launches growth hormone deficiency test in Europe

Aeterna Zentaris (NASDAQ:AEZS) said its licensing partner Consilient Health launched Ghryvelin, an oral test for diagnosing growth hormone deficiency in adults, in Europe. The company said Ghryvelin  (macimorelin) was approved in European in 2019, backed by data from a phase 3 trial showing that oral macimorelin provided accuracy comparable to that of standard insulin tolerance testing (ITT) and had a more favorable safety profile compared to ITT. Aeterna added that its  licensing partner, Novo Nordisk (NVO) is currently marketing macimorelin as Macrilen in the U.S.

For further details see:

Aeterna Zentaris licensing partner Consilient launches growth hormone deficiency test in Europe